Mirum Pharmaceuticals, Inc. (MIRM) Balance Sheet

The balance sheet has expanded rapidly, driven by a $436.7M increase in total debt from 2025Q2 to 2026Q2, which appears to fund commercial expansion and pipeline investment. However, the equity position deteriorated from $255.2M to -$10.4M over the same period, reflecting cumulative losses and a one-time $790.2M charge in 2026Q1. This suggests the company is increasingly reliant on external financing, and investors should monitor whether revenue growth can outpace debt accumulation.

The $441.6M increase in debt over four quarters appears strategic, likely funding the acquisition of Livmarli or other commercial assets, but it has inverted the equity base. With debt now exceeding total assets, the company's leverage is extreme, and the negative equity suggests that creditors bear significant risk. While the current ratio remains healthy at 2.86, the debt load may strain future cash flows, especially given the operating losses and heavy stock-based compensation.

The asset base is dominated by goodwill and intangible assets, which likely stem from acquisitions, and these carry impairment risk if expected synergies fail to materialize. The minimal PPE (1.4% of assets) confirms a highly asset-light business model, consistent with a biotech focused on commercializing acquired products. Investors should monitor goodwill for potential write-downs, especially given the recent debt-funded expansion and the company's history of net losses.

The equity base has been eroded by cumulative net losses, including a $790.2M charge in 2026Q1, and by significant stock-based compensation that exceeds operating losses. While the company has not repurchased shares, the continuous SBC issuance likely dilutes shareholders, and the negative equity position suggests that book value is no longer a meaningful measure of value. This may indicate that the company is prioritizing growth over balance sheet strength, which could be a concern for risk-averse investors.

Despite the negative equity, the company maintains a solid liquidity position, with cash covering roughly 1.2x total debt and a current ratio above 2.5. However, the cash balance increased only modestly from $228.1M a year ago, despite the $441.6M debt raise, implying that a significant portion of the proceeds was consumed by operating losses and working capital needs. Given the operating cash flow of -$273.0M in 2026Q2, the cash runway appears limited to about one year, warranting close monitoring of future financing needs.